Revumenib

Generic Name: Revumenib

Drug Type: Small Molecule

Chemical Formula: C_₃₂H_₄₇FN_₆O_₄S

CAS Number: 2169919-21-3

Unique Ingredient Identifier: LZ0M43NNF2

Clinical Trials

A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia

Phase 2

Recruiting

Conditions: Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Mixed Phenotype Acute Leukemia
Refractory Acute Myeloid Leukemia Due to Lineage Switch From Mixed Phenotype Acute Leukemia
Recurrent Mixed Phenotype Acute Leukemia
Recurrent Acute Leukemia of Ambiguous Lineage
Recurrent Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-Rearranged
Refractory Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-Rearranged
Recurrent Acute Lymphoblastic Leukemia
Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous Lineage
Refractory Acute Leukemia of Ambiguous Lineage
Refractory Acute Lymphoblastic Leukemia

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Drug: Cytarabine
Drug: Calaspargase Pegol
Procedure: Echocardiography
Drug: Fludarabine Phosphate
Drug: Hydrocortisone Sodium Succinate
Procedure: Lumbar Puncture
Drug: Methotrexate
Drug: Revumenib
Procedure: Multigated Acquisition Scan
Drug: Prednisolone
Drug: Prednisone
Drug: Vincristine Sulfate

First Posted Date: 2023-03-09

Last Posted Date: 2025-03-19

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 78

Registration Number: NCT05761171

Locations: 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
Arkansas Children's Hospital, Little Rock, Arkansas, United States
🇺🇸
Kaiser Permanente Downey Medical Center, Downey, California, United States

and more 66 locations

Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors

Phase 1

Active, not recruiting

Conditions: Colorectal Cancer
Solid Tumors

Interventions: Drug: Revumenib
Drug: Chemotherapy

First Posted Date: 2023-02-16

Last Posted Date: 2025-05-13

Lead Sponsor: Syndax Pharmaceuticals

Target Recruit Count: 42

Registration Number: NCT05731947

Locations: 🇺🇸
Honor Health Research Institute, Scottsdale, Arizona, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, Manhattan, New York, United States

and more 3 locations

Study of Radiolabeled Revumenib in Adults With Acute Leukemia

Phase 1

Completed

Conditions: Acute Leukemia

Interventions: Drug: Revumenib

First Posted Date: 2022-06-07

Last Posted Date: 2025-01-10

Lead Sponsor: Syndax Pharmaceuticals

Target Recruit Count: 9

Registration Number: NCT05406817

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)

Phase 1

Recruiting

Conditions: Acute Myeloid Leukemia

Interventions: Drug: ASTX727
Drug: SNDX-5613
Drug: Venetoclax

First Posted Date: 2022-05-04

Last Posted Date: 2025-05-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 43

Registration Number: NCT05360160

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia

Phase 1

Completed

Conditions: Relapsed/Refractory Leukemias
Acute Lymphoblastic Leukemia
Acute Lymphocytic Leukemia
Mixed Phenotype Acute Leukemia
Acute Myeloid Leukemia
Acute Undifferentiated Leukemia

Interventions: Drug: Revumenib
Drug: Chemotherapy Regimen 1
Drug: Chemotherapy Regimen 2

First Posted Date: 2022-04-13

Last Posted Date: 2024-08-13

Lead Sponsor: Syndax Pharmaceuticals

Target Recruit Count: 30

Registration Number: NCT05326516

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
University of California, San Francisco (UCSF) Benioff Children's Hospital, San Francisco, California, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 8 locations

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

Phase 1

Recruiting

Conditions: Mixed Phenotype Acute Leukemia
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Mixed Lineage Acute Leukemia
Acute Leukemia of Ambiguous Lineage

Interventions: Drug: revumenib
Drug: cobicistat

First Posted Date: 2019-08-22

Last Posted Date: 2024-11-21

Lead Sponsor: Syndax Pharmaceuticals

Target Recruit Count: 413

Registration Number: NCT04065399

Locations: 🇫🇷
Hospital Saint-Louis - APHP, Paris, France
🇫🇷
Centre Hospitalier Universitaire (CHU) de Bordeaux, Pessac, France
🇩🇪
University Hospital Of Ulm, Universitatsklinikum Ulm, Ulm, Baden-Württemberg, Germany

and more 54 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy